These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1835599)

  • 1. Plasma concentrations of CA-50 in relation to tumour burden in exocrine pancreatic cancer.
    Pålsson B; Andren-Sandberg A; Masson P
    Eur J Cancer; 1991; 27(10):1279-82. PubMed ID: 1835599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of the carbohydrate antigen CA-19-9, the carcinoembryonic antigen and alpha fetoprotein in the diagnosis of pancreatic cancer].
    Skvortsov SV; Kalinin AV; Lytsar' BN
    Vestn Ross Akad Med Nauk; 1993; (4):47-9. PubMed ID: 7687486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA 19-9 as a prognostic index after resection for pancreatic cancer.
    Sperti C; Pasquali C; Catalini S; Cappellazzo F; Bonadimani B; Behboo R; Pedrazzoli S
    J Surg Oncol; 1993 Mar; 52(3):137-41. PubMed ID: 8441267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic liver metastases after curative resection combined with intraoperative radiation for pancreatic cancer.
    Takamori H; Hiraoka T; Kanemitsu K; Tsuji T
    Hepatogastroenterology; 2004; 51(59):1500-3. PubMed ID: 15362786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of tumour markers CA 19-9 and CA-50 in sera from patients with pancreatic duct carcinoma.
    Von Rosen A; Linder S; Harmenberg U; Wiechel KL
    Surg Oncol; 1992 Apr; 1(2):109-13. PubMed ID: 1341241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 242 is a new tumor marker for pancreatic cancer.
    Röthlin MA; Joller H; Largiadèr F
    Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of B7-H4 expression in matched primary pancreatic cancer and liver metastases.
    Qian Y; Sang Y; Wang FX; Hong B; Wang Q; Zhou X; Weng T; Wu Z; Zheng M; Zhang H; Yao H
    Oncotarget; 2016 Nov; 7(44):72242-72249. PubMed ID: 27750217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.
    Colomer R; Ruibal A; Salvador L
    Cancer; 1989 Oct; 64(8):1674-81. PubMed ID: 2790682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.
    Louhimo J; Alfthan H; Stenman UH; Haglund C
    Oncology; 2004; 66(2):126-31. PubMed ID: 15138364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies.
    Mao C; Domenico DR; Kim K; Hanson DJ; Howard JM
    Arch Surg; 1995 Feb; 130(2):125-34. PubMed ID: 7848081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is CA242 really a new tumour marker for pancreatic adenocarcinoma?
    Plebani M; Basso D; Navaglia F; D'Angeli F; Panozzo MP; Del Giudice G; Battistel M; Meggiato T; Del Favero G
    Oncology; 1995; 52(1):19-23. PubMed ID: 7800337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen.
    Kishimoto T; Ishikura H; Kimura C; Takahashi T; Kato H; Yoshiki T
    Int J Cancer; 1996 Aug; 69(4):290-4. PubMed ID: 8797870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is liver resection in metastases of exocrine pancreatic carcinoma justified?].
    Klempnauer J; Ridder GJ; Piso P; Pichlmayr R
    Chirurg; 1996 Apr; 67(4):366-70. PubMed ID: 8646923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration and localization of carbohydrate antigen 19-9 in tissues of pancreatic cancer.
    Nishida K; Miyagawa H; Yoshikawa T; Kondo M
    Oncology; 1988; 45(3):166-71. PubMed ID: 3163417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of tumor-associated carbohydrate antigens correlates with hepatic metastasis of pancreatic cancer: clinical and experimental studies.
    Takamori H; Hiraoka T; Yamamoto T
    Hepatogastroenterology; 1996; 43(9):748-55. PubMed ID: 8799425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
    Plebani M; Basso D; Del Favero G; Ferrara C; Meggiato T; Fogar P; Mangano F; Ricciardi G; Burlina A
    Oncology; 1993; 50(6):436-40. PubMed ID: 8233283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.